Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2010

View Archived Issues

IntraCellular Therapies claims new PDE 1 inhibitors

Roche discloses novel PDE 10A inhibitors

Exelixis patents S1P1 receptor agonists for autoimmune diseases

Merck & Co. and Mochida claim new coagulation factor IXa inhibitors

Phase III data released on tanezumab in knee osteoarthritis pain

SB-1518 dose selected for phase II evaluation in myelofibrosis

Interim phase II data reported on ENB-0040 in childhood hypophosphatasia

Pooled phase III data show efficacy of tesamorelin in HIV-related lipodystrophy

Pilot trial finds XOMA-052 beneficial in uveitis of Behcet's disease

TroVax to be evaluated in mesothelioma in phase I/II trial

CHMP recommends approval of Shire's VPRIV for type 1 GD

Gilead signs definitive agreement to acquire CGI Pharmaceuticals

AstraZeneca and MMV join to identify antimalaria candidates

CHMP recommends approval of Sycrest for bipolar disorder

Revlimid approved in Japan for relapsed or refractory multiple myeloma

Pfizer suspends osteoarthritis program for tanezumab

MorphoSys and Xencor collaborate on mAb for B-cell malignancies

FDA sets new decision date for motavizumab BLA

Basilea presents update on phase III isavuconazole program

CHMP confirms previous negative opinion for ceftobiprole

CHMP recommends approval of vernakalant for atrial fibrillation

Pariet approved in Japan for nonerosive GERD

Galderma discloses new tyrosinase inhibitors

Corcept nears enrollment completion in phase III Corlux trial

EMA's CHMP issues positive opinion for Pharming's Rhucin

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...